Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
MannKind Corporation heads into its November 5 earnings date with short sellers retreating, options traders leaning bullish, and the Street still divided on whether the pipeline can offset near-term revenue pressure.
The clearest shift in positioning this week is in short interest. Bears have reduced exposure meaningfully over the past month: SI % FF has fallen from around 9.7% at the end of August to 8.1% now, a drop of roughly 15% in shares short. The week's move alone was a 7.5% decline in shares borrowed. That is a notable unwind for a stock that was carrying close to 30 million shares short as recently as early September. Borrow costs remain low at 0.42%, and availability is loose at over 320%, meaning there is no constraint on new shorts entering if sentiment shifts. The unwind looks like conviction fading, not a squeeze.
Options positioning reinforces that read, but from the other side. The put/call ratio has dropped to 0.15, well below its 20-day average of 0.18 and close to the 52-week low of 0.13. That is an unusually call-heavy market, with traders expressing a directional view that MNKD has room to move higher before the November print. The z-score of negative 1.0 confirms the skew is more extreme than it looks on the surface. The stock is up 11% on the week despite a 2.9% pullback on Tuesday, so some of that call demand may have been opened into, rather than ahead of, the recent rally.
The Street has been quietly trimming targets while holding constructive ratings. Truist Securities lowered its price target to $5 from $6 this week, maintaining a Buy. Wells Fargo has cut twice since the Q2 print in August, moving from $14 down to $13 and retaining Overweight. Cantor Fitzgerald reiterated Overweight with an $8 target in September. The consensus target of around $7.72 implies more than 100% upside from the current price of $3.71, though that gap partly reflects targets set during a stronger period for the stock, which is down 41% year-to-date. The bull case rests on FUROSCIX revenue guidance of $110 to $120 million for 2026, the inhaled pulmonary fibrosis pipeline via Tyvaso DPI and ralinepag DPI, and a pediatric Afrezza PDUFA that could expand the addressable market. Bears point to heavy dependence on United Therapeutics' execution, royalty revenue that consensus models as declining from 2027, and a Q1 revenue miss of $90.2 million against a $105.4 million estimate. Balance-sheet fragility, flagged in the ORTEX factor scores with an EV/EBIT rank near the bottom of the universe, adds another layer of caution.
On the institutional side, BlackRock added 3.5 million shares in the quarter ending September 30, lifting its stake to just under 10% of shares. Rubric Capital Management, which built a new 18 million share position through June, has not updated its filing since August. Deep Track Capital and Braidwell both appear as new entrants in the June-quarter data, each with positions in the 3 to 6 million share range. No 13D activist is on the register. Insider activity has been entirely mechanical: director Steven Binder has sold small tranches in July, August, and September, all under a pre-arranged 10b5-1 plan, which strips out any signalling value from those trades.
The short-score history offers one note of caution. The ORTEX short score sits at 58.8, down from a recent peak above 62 in late September. That softening aligns with the short-interest unwind but still leaves the score in moderately elevated territory. Peers have been broadly weak this week. IPSC fell 20% over the period and AVTX dropped nearly 13%, while MNKD's 11% gain stood out against the group. With earnings on November 5, the next inflection point for positioning is whether the FUROSCIX revenue trajectory and any pipeline update can close the gap between where the Street is anchoring targets and where the stock is actually trading.
See the live data behind this article on ORTEX.
Open MNKD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
